WashingtonTrumpRx added generic medicines to its catalogue.
The US government portal had covered only branded drugs under negotiated discounts; generics are the first category added to the direct-purchase channel.
The expansion bypasses pharmacy benefit managers, intermediaries that dominate US drug pricing.
Sources: STAT
WHAT A PBM ACTUALLY DOES
Pharmacy benefit managers sit between insurers, drugmakers, and pharmacies. They negotiate rebates from manufacturers, set formularies (which drugs get covered), and decide what pharmacies are paid. They don't make drugs and don't dispense them — they manage the flow of money around both.
THE REBATE GAME
PBMs take a cut of the rebate a manufacturer pays to get a drug on the formulary. A higher list price funds a bigger rebate, which funds a bigger PBM cut — so the incentive runs toward higher sticker prices, not lower ones. The patient at the counter pays a copay based on the list price, not the post-rebate net.
WHY GENERICS ARE DIFFERENT
A generic drug is chemically identical to its branded original but sold after patent expiry by any qualified manufacturer. Competition typically drives generic prices to within a few percent of production cost — often pennies per pill. Roughly 90% of US prescriptions are now filled with generics, but they account for under 20% of drug spending.
THE SPREAD PRICING TRICK
On generics, PBMs often charge the insurer one price and reimburse the pharmacy a lower one, pocketing the difference. The patient, the pharmacist, and even the insurer's HR department typically can't see the spread. Several state Medicaid audits found PBMs netting 20-30% on this gap alone.
THE MARK CUBAN PRECEDENT
Cost Plus Drugs launched in 2022 selling generics at manufacturer cost plus a flat 15% markup and a small dispensing fee. Imatinib (leukemia) that retailed for $2,500/month at PBM-mediated pharmacies sold for around $30. The arithmetic exposed how much of the US generic price was intermediation, not medicine.
THE HATCH-WAXMAN BARGAIN
The 1984 Hatch-Waxman Act created the modern generics industry by letting manufacturers piggyback on the originator's FDA safety data once patents expired. In exchange, branded drugmakers got patent-term restoration for time lost in trials. The deal birthed both the cheap-generic market and the patent-extension games (evergreening, pay-for-delay) that still shape US drug pricing today.